Clinical trial
SU5416 in Treating Patients With Malignant Mesothelioma
NCT00006014 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006014 |
|---|---|
| Title | SU5416 in Treating Patients With Malignant Mesothelioma |
| Official title | A Phase II Trial of SU5416 (NSC# 696819) in Patients With Malignant Mesothelioma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Mesothelioma |
| Intervention type | Drug |
| Interventions | semaxanib |
| Enrollment | 45 |
| Start date | Aug 1, 2000 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2009 |
| First posted | Feb 26, 2004 |
| Last update posted | Jun 3, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: